Publications by authors named "Mark Wedel"

Claim this Profile
A
Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
Jeremy D Furtado, Mark K Wedel, Frank M Sacks

J Lipid Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
Fatima Akdim, Diane L Tribble, JoAnn D Flaim, Rosie Yu, John Su, Mark K Wedel

Eur Heart J· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
Fatima Akdim, Erik S G Stroes, Eric J G Sijbrands, Diane L Tribble, Mieke D Trip, Mark K Wedel

J Am Coll Cardiol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Rosie Z Yu, Kristina M Lemonidis, Mark J Graham, John E Matson, Rosanne M Crooke, Mark K Wedel

Biochem Pharmacol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
Rosie Z Yu, Richard S Geary, Joann D Flaim, Gina C Riley, Diane L Tribble, Mark K Wedel

Clin Pharmacokinet· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Bruce Yacyshyn, William Y Chey, Mark K Wedel, Rosie Z Yu, David Paul

Clin Gastroenterol Hepatol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Richard S Geary, JoAnn D Bradley, Tanya Watanabe, Younggil Kwon, Mark Wedel

Clin Pharmacokinet· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.
John J P Kastelein, Mark K Wedel, Brenda F Baker, John Su, JoAnn D Bradley

Circulation· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial liquid ventilation in adult patients with acute respiratory distress syndrome.
Robert M Kacmarek, Herbert P Wiedemann, Philip T Lavin, Mark K Wedel, Ahmet S Tütüncü

Am J Respir Crit Care Med· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis